Hugel has been developing and introducing new technologies based on botulinum toxin manufacturing technology in cooperation with the best researchers at home and abroad, mainly in the field of cosmetic surgery and therapeutics.
Hugel creates new value through continuous management innovation and is evolving into a truly global biopharmaceutical company.VIEW MORE
Hugel has been developing into a truly global biopharmaceutical company by constantly creating new value, and we will continue to lead the way for Korea to become a powerhouse in the bio sector.
Hugel Achieves Record-High Performance ..
Recent Publication Confirms the Efficacy..
Letybo, Hugel’s Botulinum Toxin, Obtain..
Hugel held Extraordinary Meeting of Gen..
Hugel accelerates the leap forward as a ..
Hugel reported1Q22revenue of KRW64.9bn ..
We will provide maximum investment value through securing future growth engines.